Paclitaxel, docetaxel, and vinorelbine have been approved for chemotherapy in patients with advanced breast cancer that is resistant to anthracyclines.
Selecting which agent to use is difficult because each possesses advantages and disadvantages related to clinical response, toxicity, method of administration, and cost.
A cost-utility analysis was therefore performed to create a rank order on the basis of effectiveness, quality of life, and economic considerations.
Eighty-eight anthracycline-resistant breast cancer patients who had received paclitaxel (n=34), docetaxel (n=29), or vinorelbine (n=25) during the past 2 years were identified.
Total resource consumption was collected, which included expenditures for chemotherapy, supportive care, laboratory tests, management of adverse effects, and all related physician fees.
Utilities from 25 oncology care providers and 25 breast cancer patients were estimated using the time trade-off technique.
The economic estimates from the chart review and clinical data from the literature were then modeled using the principles of decision analysis.
Each of the three drugs led to a similar duration of quality-adjusted progression-free survival (paclitaxel, 37.2 days ; docetaxel, 33.6 days ; vinorelbine, 38.0 days). (...)
Mots-clés Pascal : Tumeur maligne, Glande mammaire, Anticancéreux, Paclitaxel, Antimitotique, Association médicamenteuse, Docétaxel, Stade avancé, Résistance traitement, Vinorelbine, Anthracyclines, Analyse avantage coût, Chimiothérapie, Traitement, Economie santé, Homme, Taxane dérivé, Alcaloïde, Glande mammaire pathologie
Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Antineoplastic agent, Paclitaxel, Antimitotic, Drug combination, Docetaxel, Advanced stage, Negative therapeutic reaction, Vinorelbine, Anthracyclins, Cost benefit analysis, Chemotherapy, Treatment, Health economy, Human, Taxane derivatives, Alkaloid, Mammary gland diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0487742
Code Inist : 002B02R02. Création : 22/03/2000.